tiprankstipranks
Trending News
More News >
Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
Australian Market

Genetic Signatures Ltd. (GSS) AI Stock Analysis

Compare
5 Followers

Top Page

AU

Genetic Signatures Ltd.

(Sydney:GSS)

45Neutral
Genetic Signatures Ltd. is facing significant financial performance challenges, with declining revenues and negative profit margins weighing heavily on its score. The technical indicators show a bearish trend, further adding to the company's struggles. The valuation metrics do not provide any compensating strengths, as the negative P/E ratio and absence of dividend yield limit its attractiveness. Overall, the stock score reflects the company's need for strategic improvements to enhance its financial stability and market competitiveness.

Genetic Signatures Ltd. (GSS) vs. S&P 500 (SPY)

Genetic Signatures Ltd. Business Overview & Revenue Model

Company DescriptionGenetic Signatures Ltd. (GSS) is an Australian-based molecular diagnostics company specializing in the development and commercialization of advanced molecular diagnostic solutions. The company focuses on simplifying and accelerating the detection of infectious diseases through its proprietary 3base™ technology, which is employed in their range of EasyScreen™ diagnostic kits. These kits are designed for use in clinical laboratories to detect a broad spectrum of pathogens, including bacteria, viruses, and protozoa, with high accuracy and efficiency.
How the Company Makes MoneyGenetic Signatures Ltd. generates revenue primarily through the sale of its EasyScreen™ diagnostic kits to clinical laboratories and healthcare facilities. The company benefits from the growing demand for rapid and reliable diagnostic testing, driven by the need for timely detection and response to infectious diseases. Key revenue streams include direct sales of diagnostic kits and reagents, as well as potential licensing agreements for its proprietary 3base™ technology. Partnerships with healthcare institutions and research organizations contribute to the company's market presence and distribution capabilities, enhancing its ability to reach broader markets and drive sales growth.

Genetic Signatures Ltd. Financial Statement Overview

Summary
Genetic Signatures Ltd. faces significant challenges in maintaining revenue and profitability, with declining revenues and negative profit margins. While the balance sheet is relatively stable with low debt levels, the negative cash flows highlight underlying liquidity issues. The company may need to explore operational efficiencies and revenue growth strategies to improve its financial health.
Income Statement
30
Negative
The company has shown a significant decline in revenue from 2023 to 2024, with a negative revenue growth rate. Profitability metrics like gross profit margin and net profit margin are negative, indicating operational challenges. The negative EBIT and EBITDA margins further highlight the company's struggles in maintaining operational efficiency.
Balance Sheet
65
Positive
The company maintains a healthy equity position with a high equity ratio and low debt-to-equity ratio, indicating financial stability. However, the decline in equity from 2023 to 2024 suggests potential risks in sustaining this stability in the long term. The return on equity is negative, reflecting the company's unprofitability.
Cash Flow
50
Neutral
Operating cash flow and free cash flow are negative, posing liquidity concerns. The company witnessed a significant cash outflow in recent years. However, the financing cash flow has been positive, indicating reliance on external funding sources to manage operations.
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
9.77M16.94M35.42M28.28M11.26M
Gross Profit
4.31M-12.74M7.21M4.27M-2.37M
EBIT
-22.33M-18.89M2.97M1.56M-4.83M
EBITDA
-19.82M-13.14M4.70M3.22M-1.70M
Net Income Common Stockholders
-17.86M-14.05M3.06M1.76M-2.09M
Balance SheetCash, Cash Equivalents and Short-Term Investments
36.25M16.35M36.90M30.12M31.18M
Total Assets
67.29M49.08M59.65M54.05M49.72M
Total Debt
1.22M0.0034.00K399.00K741.00K
Net Debt
-35.03M-16.35M-36.86M-29.72M-30.43M
Total Liabilities
6.18M6.16M4.85M4.71M3.79M
Stockholders Equity
61.10M42.91M54.80M49.34M45.93M
Cash FlowFree Cash Flow
-14.91M-20.54M6.82M-784.00K-11.84M
Operating Cash Flow
-10.12M-12.45M9.81M4.20M-9.49M
Investing Cash Flow
-4.79M-8.09M-2.99M-4.98M-2.35M
Financing Cash Flow
34.81M-23.00K-101.00K-190.00K36.69M

Genetic Signatures Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.50
Price Trends
50DMA
0.49
Positive
100DMA
0.55
Negative
200DMA
0.62
Negative
Market Momentum
MACD
<0.01
Negative
RSI
58.93
Neutral
STOCH
97.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GSS, the sentiment is Positive. The current price of 0.5 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.49, and below the 200-day MA of 0.62, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.93 is Neutral, neither overbought nor oversold. The STOCH value of 97.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:GSS.

Genetic Signatures Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUTLX
72
Outperform
$9.91B193.1114.52%55.85%893.42%
AURAC
54
Neutral
AU$204.99M-37.20%32.02%
52
Neutral
$5.23B3.70-41.86%2.84%16.58%-0.16%
AUGSS
45
Neutral
AU$113.57M-47.52%44.61%16.40%
AUPIQ
44
Neutral
AU$51.76M-131.55%12.53%-11.04%
AUBDX
42
Neutral
AU$29.64M-104.23%-17.26%
AUIMU
37
Underperform
$179.21M-99.05%-34.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:GSS
Genetic Signatures Ltd.
0.52
-0.20
-27.78%
AU:TLX
Telix Pharmaceuticals
27.10
11.82
77.36%
AU:IMU
Imugene Limited
0.02
-0.05
-70.67%
AU:BDX
BCAL Diagnostics Limited
0.08
-0.02
-20.00%
AU:RAC
Race Oncology Ltd.
1.16
-0.10
-7.94%
AU:PIQ
Proteomics International Laboratories Ltd.
0.37
-0.67
-64.42%

Genetic Signatures Ltd. Corporate Events

Genetic Signatures Reports 71% Sales Increase and Secures First US Contract
Apr 30, 2025

Genetic Signatures Ltd reported a significant 71% increase in quarterly sales, reaching $2.9 million, driven by high respiratory testing rates in Australia. The company signed its first US commercial contract for its EasyScreen™ Gastrointestinal Parasite Detection Kit and is implementing a new strategy for automated, high throughput solutions through the customization of commercially available instruments. With a strong cash balance of $37.4 million, Genetic Signatures is well-positioned to expand its market presence, particularly in the US, following FDA clearance. The company continues to focus on innovation in assay development, workflow enhancements, and software improvements to support its growth strategy.

Genetic Signatures Ltd. Announces Cessation of Securities
Feb 28, 2025

Genetic Signatures Ltd. announced the cessation of 380,000 securities due to the lapse of conditional rights, as the conditions for these securities were not met or became unfeasible. This cessation may impact the company’s capital structure and could influence investor perceptions regarding the company’s future financial strategies.

Genetic Signatures Reports Strong Sales Growth and Strategic Shift in FY25
Feb 26, 2025

Genetic Signatures Ltd. reported a significant 136% increase in sales for the first half of FY25, reaching $8.5 million, driven by strong respiratory sales in Australia. The company improved its gross margin to 59% and reduced its underlying loss by 20% compared to the previous year. Despite a statutory loss of $15.2 million due to a $6.8 million impairment expense, Genetic Signatures secured its first US commercial contract, marking a strategic expansion into the US market. The company has shifted its strategic direction towards developing a more cost-effective and faster-to-market automated solution, ceasing the development of its Next Generation instrument. This new approach is expected to enhance its syndromic infectious disease testing capabilities, leveraging its 3base technology.

Genetic Signatures Reports Revenue Surge Amid Rising Losses
Feb 26, 2025

Genetic Signatures Limited reported a 136% increase in revenues to $8,499,000 for the half-year ending December 31, 2024, despite a 45% rise in losses to $15,200,000 compared to the previous year. The significant revenue growth highlights the company’s expanding market presence, although the increased losses suggest ongoing financial challenges, impacting stakeholder confidence and future strategic decisions.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.